Friday, 18 Oct 2019

You are here

2015 Guidelines for Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing form of interstitial pneumonia, with poor survival rates of nearly 50% at 3 years. There are new joint guidelines for IPF from a conglomerate of international experts including the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and the Latin American Thoracic Association (Citation source http://buff.ly/1D6V4A2).

The guidelines make strong or conditional recommendations for or against specific agents. Strong recommendations are made against the use of warfarin; imatinib (a selective tyrosine kinase inhibitor); and ambrisentan (a selective endothelin receptor antagonist). Conditional recommendations are made against sildenafil  (a phosphodiesterase-5 inhibitor); and the dual endothelin receptor antagonists, macitentan and bosentan. Two new agents have been given conditional recommendations: nintedanib, a tyrosine kinase inhibitor; and pirfenidone, an oral antifibrotic drug. Pooled data on nintedanib show no significant effect on mortality or acute exacerbations of IPF, but a reduction in decline of forced vital capacity (FVC). Available trial data for pirfenidone show both a reduction in mortality and a reduced rate of FVC decline.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Protective Effects of ASA and Vasodilators in Systemic Sclerosis

A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable  cardiovascular outcomes.

Myositis Patients at High Risk of Opportunistic Infections

Among patients with systemic rheumatic diseases, the highest incidence of opportunistic infections was seen in those with polymyositis/dermatomyositis (PM/DM), Taiwanese researchers found.

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.

Declining Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis Mortality in the USA

Annals of Internal Medicine reports that age-adjusted mortality rates for antineutrophil cytoplasmic autoantibody–associated vasculitides (AAV) have improved over time - with a decline of nearly 2 percent per year in the United States from 1999 to 2017. Nevertheless, long-term outcomes continue to lag behind mortality rates of the general population.

Serum Interferon Predicts Lupus Flares

Elevated serum levels of interferon-α among patients whose systemic lupus erythematosus (SLE) was in remission helped predict future disease flares, European researchers found.

Among 254 SLE patients who were in remission, 26% had abnormally high serum levels of interferon-α at baseline, according to Alexis Mathian, MD, of Pitié-Salpêtrière Hospital in Paris, and colleagues.